ABSTRACT
Background With the rising life expectancy and an ageing population, it has become increasingly important to investigate treatments suitable for older adult patients with esophageal cancer. This study investigated whether older adult patients who underwent esophagectomy had better clinical outcomes than those who were non-surgically treated.
Materials and methods We retrospectively analyzed patients with esophageal squamous cell carcinoma (ESCC) who were 70 years or older and underwent esophagectomy, radiotherapy (RT), and/or chemotherapy (CT) from January 2018 to December 2019. Patients were divided into two groups: the surgery group (S group) and non-surgery group (NS group). Then compared the clinical outcomes of the two groups.
Results After a median follow-up duration of 36.6 months, the S group showed better OS. The 3-year OS was 59% in the S group and 27% in the NS group (HR, 0.397; 95% CI, 0.278–0.549; P<0.0001). In the S group, the median progression free survival was 38.3 months (95% CI, 30.6–46.1) compared to 12.3 months in the NS group (HR, 0.511; 95% CI, 0.376–0.695; P<0.0001). In addition, the number of adverse events in the NS group was higher than that in the S group (P<0.001)
Conclusion Overall, patients with ESCC ≥70 years who underwent esophagectomy had significantly better clinical outcomes than those who underwent non-surgical treatment with RT and/or CT.
What is already known on this topic – There was a lack of comprehensive research specifically focusing on older adult patients with ESCC and comparing the outcomes of surgical and non-surgical treatments. Given the rising life expectancy and aging population, it became increasingly important to investigate appropriate treatment options for older adult patients with esophageal cancer. This study aimed to fill the gap in knowledge by retrospectively analyzing patients with ESCC who were 70 years or older and underwent different treatment modalities such as esophagectomy, radiotherapy (RT), and/or chemotherapy (CT).By conducting this study, the researchers aimed to provide valuable insights into the optimal treatment approach for older adult patients with ESCC. Understanding the comparative effectiveness and safety of surgical versus non-surgical treatments would help clinicians make informed decisions when managing and treating this specific patient population.
What this study adds – In addition to the research discussion on OS and DFS, this study also increased the comparison of Adverse events of different treatments in elderly ESCC patients.
How this study might affect research, practice or policy – In the treatment practice of elderly patients with ESCC, it is suggested that surgical treatment is possible.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the National Key Research and Development Program (2022YFC2403400), International Cooperation Projects of Science and Technology Department of Sichuan Province (Grant No. 2020YFH0169), the Sichuan Key Research and Development Project from Science and Technology Department of Sichuan Province (Grant No. 2023YFS0044, 2023YFQ0056, 2023YFS0488 and 2023YFQ0055), the Wu Jieping Clinical Research Projects (Grant No. 320.6750.2020-15-3), and Sichuan Province Clinical Key Specialty Construction Project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This retrospective study was reviewed by the Ethics Committee (EC) for Medical Research and New Medical Technology of Sichuan Cancer Hospital (SCCHEC-02-2022-050). The data are anonymous, and the requirement for informed consent was therefore waived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos